GSK-3β inhibition presents a new method for reducing the formation of both neurofibrillary tangles and amyloid plaques, two of Alzheimer's disease's pathological hallmarks [47]. This evidence concerns the gene GSK3B and early-onset autosomal dominant Alzheimer disease.